# Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

> **NCT06558604** · PHASE2 · RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 100 (estimated)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Glofitamab
- **DRUG:** Venetoclax Oral Product
- **DRUG:** Zanubrutinib Oral Capsule

## Key facts

- **NCT ID:** NCT06558604
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2028-05
- **Final completion:** 2032-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558604, "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06558604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*